2024
The combination of donepezil and cognitive training for improving treatment outcomes for alcohol use disorder: Design of a randomized controlled trial
Yoon G, Sofuoglu M, Petrakis I, Pittman B, Bell M. The combination of donepezil and cognitive training for improving treatment outcomes for alcohol use disorder: Design of a randomized controlled trial. Contemporary Clinical Trials 2024, 145: 107657. PMID: 39111388, PMCID: PMC11423257, DOI: 10.1016/j.cct.2024.107657.Peer-Reviewed Original ResearchCognitive remediation therapyAlcohol use disorderAlcohol use disorder treatment outcomesNeurocognitive functionCombination of donepezilRemediation therapyUse disorderTreatment outcomesDevelopment of alcohol use disordersReduce heavy drinking daysHeavy drinking daysGlobal neurocognitive functioningImprove neurocognitive functionEnhanced neurocognitive functionImprove cognitive functionRandomized controlled trialsReduce alcohol consumptionNeurobiological evidenceDrinking daysNeurocognitive function scoresCognitive trainingVA Connecticut Healthcare SystemCognitive functionImprove treatment outcomesCognitive impairmentAltered corollary discharge in the auditory cortex could reflect louder inner voice experience in patients with verbal hallucinations, a pilot fMRI study
Stephane M, Dzemidzic M, Yoon G. Altered corollary discharge in the auditory cortex could reflect louder inner voice experience in patients with verbal hallucinations, a pilot fMRI study. Schizophrenia Research 2024, 265: 14-19. PMID: 38448353, DOI: 10.1016/j.schres.2024.03.001.Peer-Reviewed Original ResearchConceptsAuditory verbal hallucinationsTemporal cortex activationPost-stimulus stageVerbal hallucinationsFMRI studyHearing conditionsCortex activityPilot fMRI studyLeft Heschl's gyrusAuditory cortexFinite impulse response basis functionsPermutation-based analysisConsistent with prior literatureBOLD fMRI studiesInner voiceSignificant group interactionHeschl's gyrusHallucinationsPrimary auditory cortexDischarge deficitsVoice experiencesDeficitsHealthy controlsAnalysis of varianceCortex
2023
Progesterone Attenuates the Stress Response in Individuals with Alcohol Dependence and Post-Traumatic Stress Disorder – A Pilot Study
Ralevski E, Newcomb J, Pisani E, DeNegre D, Peltier M, Jane J, Yoon G, Petrakis I. Progesterone Attenuates the Stress Response in Individuals with Alcohol Dependence and Post-Traumatic Stress Disorder – A Pilot Study. Journal Of Dual Diagnosis 2023, 20: 39-51. PMID: 38147491, PMCID: PMC11214330, DOI: 10.1080/15504263.2023.2294989.Peer-Reviewed Original ResearchAlcohol use disorderStress-induced cravingCognitive performanceNegative affectNeutral scriptsStress disorderPost-traumatic stress disorderComorbid alcohol use disorderTraumatic Stress DisorderMeasures of cravingCurrent alcohol use disorderPositive emotionsTrauma scriptsPhysiological measuresCravingStress-induced symptomsTest sessionsPTSDAnxietyAffectUse disordersLaboratory sessionsCocaine dependenceAlcohol dependenceIndividuals
2017
Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial
Mohamed S, Johnson GR, Chen P, Hicks PB, Davis LL, Yoon J, Gleason TC, Vertrees JE, Weingart K, Tal I, Scrymgeour A, Lawrence DD, Planeta B, Thase ME, Huang GD, Zisook S, Rao S, Pilkinton P, Wilcox J, Iranmanesh A, Sapra M, Jurjus G, Michalets J, Aslam M, Beresford T, Anderson K, Fernando R, Ramaswamy S, Kasckow J, Westermeyer J, Yoon G, D’Souza D, Larson G, Anderson W, Klatt M, Fareed A, Thompson S, Carrera C, Williams S, Juergens T, Albers L, Nasdahl C, Villarreal G, Winston J, Nogues C, Connolly K, Tapp A, Jones K, Khatkhate G, Marri S, Suppes T, LaMotte J, Hurley R, Mayeda A, Niculescu A, Fischer B, Loreck D, Rosenlicht N, Lieske S, Finkel M, Little J. Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial. JAMA 2017, 318: 132-145. PMID: 28697253, PMCID: PMC5817471, DOI: 10.1001/jama.2017.8036.Peer-Reviewed Original ResearchConceptsMajor depressive disorderAcute treatment phaseDepressive disorderSwitch groupAdverse effectsTreatment phaseUS Veterans Health Administration medical centersVeterans Health Administration medical centersNonpsychotic major depressive disorderWeeks of treatmentEffects of antidepressantsLikelihood of remissionSignificant treatment differencesBupropion monotherapyRandomized patientsRemission rateBupropion groupSecondary outcomesPrimary outcomeAtypical antipsychoticsDifferent antidepressantsFirst antidepressantClinical trialsCurrent treatmentMedical Center